niacin has been researched along with Exanthem in 13 studies
Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.
vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).
nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pellagra is caused by niacin (vitamin B3) deficiency and patients with pellagra present with a characteristic rash." | 8.12 | Isoniazid-associated pellagra during mass scale-up of tuberculosis preventive therapy: a case-control study. ( Auld, AF; Buono, N; Chilikutali, L; Chisuwo, L; Chiwaula, MJ; da Silva, R; Girma, B; Gunde, LJ; Gutreuter, S; Jahn, A; Kalua, T; Kaunda, E; Kim, EJ; Kumwenda, T; Maida, A; Maphosa, T; Marshall, RE; Mbewe, K; Mekonnen, TF; Melgar, M; Mhango, V; Moffitt, A; Mponda, K; Mtoto, F; Muula, AS; Mwamale, S; Mwenyeheri, G; Nabity, SA; Nagoli, E; Ngongonda, D; Nyirenda, R; Odo, M; Oeltmann, JE; Sharma, AJ; Sunguti, J; Surie, D; Williams, AM; Woelk, G; Zimba, SB, 2022) |
| "The relationship of the exanthematous eruption with lower body weight and the increase in dosage suggests a pharmacokinetic effect that may be related to increased exposure to niacin or its metabolites and provoked by inhibition of the DP1 receptor with laropiprant, as we have not seen this rash with niacin used alone." | 7.79 | A high incidence of exanthematous eruption associated with niacin/laropiprant combination in Hong Kong Chinese patients. ( Chang, M; Hu, M; Tomlinson, B; Yang, YL, 2013) |
| "Pellagra is caused by niacin (vitamin B3) deficiency and patients with pellagra present with a characteristic rash." | 4.12 | Isoniazid-associated pellagra during mass scale-up of tuberculosis preventive therapy: a case-control study. ( Auld, AF; Buono, N; Chilikutali, L; Chisuwo, L; Chiwaula, MJ; da Silva, R; Girma, B; Gunde, LJ; Gutreuter, S; Jahn, A; Kalua, T; Kaunda, E; Kim, EJ; Kumwenda, T; Maida, A; Maphosa, T; Marshall, RE; Mbewe, K; Mekonnen, TF; Melgar, M; Mhango, V; Moffitt, A; Mponda, K; Mtoto, F; Muula, AS; Mwamale, S; Mwenyeheri, G; Nabity, SA; Nagoli, E; Ngongonda, D; Nyirenda, R; Odo, M; Oeltmann, JE; Sharma, AJ; Sunguti, J; Surie, D; Williams, AM; Woelk, G; Zimba, SB, 2022) |
| " Based on the characteristics of the dermatitis and on a rapid response to niacin replacement, the diagnosis of pellagra was carried out." | 3.80 | Pellagra in a patient with primary Sjögren's syndrome. ( Ben Ghorbel, I; Chelly, I; Houman, H; Litaiem, N, 2014) |
| "The relationship of the exanthematous eruption with lower body weight and the increase in dosage suggests a pharmacokinetic effect that may be related to increased exposure to niacin or its metabolites and provoked by inhibition of the DP1 receptor with laropiprant, as we have not seen this rash with niacin used alone." | 3.79 | A high incidence of exanthematous eruption associated with niacin/laropiprant combination in Hong Kong Chinese patients. ( Chang, M; Hu, M; Tomlinson, B; Yang, YL, 2013) |
| "Niacin has beneficial effects on plasma lipoproteins and has demonstrated clinical benefits in reducing cardiovascular events and atherosclerosis progression." | 2.44 | Safety considerations with niacin therapy. ( Bays, HE; Guyton, JR, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (23.08) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 4 (30.77) | 24.3611 |
| 2020's | 4 (30.77) | 2.80 |
| Authors | Studies |
|---|---|
| Nabity, SA | 1 |
| Mponda, K | 1 |
| Gutreuter, S | 1 |
| Surie, D | 1 |
| Zimba, SB | 1 |
| Chisuwo, L | 1 |
| Moffitt, A | 1 |
| Williams, AM | 1 |
| Sharma, AJ | 1 |
| Marshall, RE | 1 |
| Chiwaula, MJ | 1 |
| da Silva, R | 1 |
| Kumwenda, T | 1 |
| Chilikutali, L | 1 |
| Mwamale, S | 1 |
| Nagoli, E | 1 |
| Mwenyeheri, G | 1 |
| Ngongonda, D | 1 |
| Kaunda, E | 1 |
| Mtoto, F | 1 |
| Mhango, V | 1 |
| Mbewe, K | 1 |
| Melgar, M | 1 |
| Odo, M | 1 |
| Jahn, A | 1 |
| Buono, N | 1 |
| Maida, A | 1 |
| Girma, B | 1 |
| Kalua, T | 1 |
| Nyirenda, R | 1 |
| Sunguti, J | 1 |
| Woelk, G | 1 |
| Gunde, LJ | 1 |
| Mekonnen, TF | 1 |
| Maphosa, T | 1 |
| Kim, EJ | 1 |
| Auld, AF | 1 |
| Muula, AS | 1 |
| Oeltmann, JE | 1 |
| Yano, H | 1 |
| Kinjo, M | 1 |
| Yang, YL | 1 |
| Hu, M | 1 |
| Chang, M | 1 |
| Tomlinson, B | 1 |
| THIERS, H | 1 |
| RACOUCHOT, J | 1 |
| FERRIERA-MARQUES, J | 1 |
| van UDEN, N | 1 |
| Guyton, JR | 1 |
| Bays, HE | 1 |
| Morse, JW | 1 |
| Morse, SJ | 1 |
| Patterson, J | 1 |
| Alagesan, M | 1 |
| Chidambaram, Y | 1 |
| Tew, JC | 1 |
| Harrington, L | 1 |
| Elsayed, H | 1 |
| Mlawa, G | 1 |
| Dalla, A | 1 |
| Kumar, S | 1 |
| De, D | 1 |
| Ben Ghorbel, I | 1 |
| Litaiem, N | 1 |
| Chelly, I | 1 |
| Houman, H | 1 |
| Kesty, K | 1 |
| De Luca, JF | 1 |
| Taylor, SL | 1 |
| Sangueza, OP | 1 |
| BOITTELLE, G | 1 |
| BOITTELLE-LENTULO, C | 1 |
| SERRIER, J | 1 |
| HOURCARD, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Niacin Supplementation on Systemic Nicotinamide Adenine Dinucleotide (NAD+) Metabolism, Physiology and Muscle Performance in Healthy Controls and Mitochondrial Myopathy Patients[NCT03973203] | 15 participants (Actual) | Interventional | 2014-06-01 | Completed | |||
| NiaMIT (NiaMIT_0001) Continuation for Early-stage Mitochondrial Myopathy Patients to Investigate the Effect of Niacin Supplementation on Systemic Nicotinamide Adenine Dinucleotide (NAD+) Metabolism, Physiology and Muscle Performance[NCT04538521] | 3 participants (Actual) | Interventional | 2019-02-11 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for niacin and Exanthem
| Article | Year |
|---|---|
Safety considerations with niacin therapy.
Topics: Cardiovascular Diseases; Chemical and Drug Induced Liver Injury; Chemistry, Pharmaceutical; Clinical | 2007 |
Safety considerations with niacin therapy.
Topics: Cardiovascular Diseases; Chemical and Drug Induced Liver Injury; Chemistry, Pharmaceutical; Clinical | 2007 |
Safety considerations with niacin therapy.
Topics: Cardiovascular Diseases; Chemical and Drug Induced Liver Injury; Chemistry, Pharmaceutical; Clinical | 2007 |
Safety considerations with niacin therapy.
Topics: Cardiovascular Diseases; Chemical and Drug Induced Liver Injury; Chemistry, Pharmaceutical; Clinical | 2007 |
12 other studies available for niacin and Exanthem
| Article | Year |
|---|---|
Isoniazid-associated pellagra during mass scale-up of tuberculosis preventive therapy: a case-control study.
Topics: Antitubercular Agents; Case-Control Studies; Exanthema; Female; HIV Infections; Humans; Isoniazid; M | 2022 |
Pruritic Rash and Diarrhea.
Topics: Aged, 80 and over; Diarrhea; Exanthema; Fatal Outcome; Female; Humans; Niacin; Pellagra; Pruritus; S | 2021 |
A high incidence of exanthematous eruption associated with niacin/laropiprant combination in Hong Kong Chinese patients.
Topics: Adult; Aged; Anti-Inflammatory Agents; Biopsy; Body Weight; Drug Combinations; Drug Eruptions; Exant | 2013 |
[Eruptions following therapeutic use of nicotinic acid for vasodilation].
Topics: Autonomic Nervous System Diseases; Exanthema; Humans; Niacin; Nicotinic Acids; Vasodilation | 1952 |
[Combined penicillin-nicotinic acid therapy of lichen ruber verrucosus].
Topics: Exanthema; Humans; Lichen Planus; Lichens; Niacin; Nicotinic Acids; Penicillins; Psychotherapy, Mult | 1950 |
Niacin reaction: common vitamin, uncommon ED diagnosis.
Topics: Adult; Diagnosis, Differential; Edible Grain; Exanthema; Humans; Hypersensitivity, Immediate; Male; | 1999 |
Pellagra.
Topics: Diarrhea; Exanthema; Female; Humans; Middle Aged; Neck; Pellagra; Skin | 2022 |
Pellagra as a differential diagnosis in the confused patient on the acute medical unit.
Topics: Alcoholism; Confusion; Diagnosis, Differential; Diarrhea; Exanthema; Humans; Male; Pellagra; Substan | 2022 |
Elderly patient of Crohn's disease with dementia and edematous red plaques on dorsum of hands.
Topics: Aged; Crohn Disease; Dementia; Diarrhea; Exanthema; Hand; Humans; Male; Pellagra | 2019 |
Pellagra in a patient with primary Sjögren's syndrome.
Topics: Adult; Exanthema; Facial Dermatoses; Female; Hand Dermatoses; Humans; Pellagra; Sjogren's Syndrome; | 2014 |
Scaly Erythematous Acral Eruption: Question. Scaly erythematous acral eruption.
Topics: Adult; Erythema; Exanthema; Female; Hand Dermatoses; Humans; Pellagra | 2016 |
[Pellagroid eruption associated with mental disorders in an alcoholic].
Topics: Alcoholism; Exanthema; Humans; Mental Disorders; Pellagra | 1950 |